< Back to previous page
Researcher
Paul Declerck
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 30 Sep 2023
Projects
1 - 10 of 28
- An integrated platform for the identification, isolation and characterization of human clock antibodies.From1 Jul 2021 → TodayFunding: Department Coordination
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Anti-tau intrabodies for the treatment of Alzheimer’s diseaseFrom1 Feb 2020 → 19 Feb 2024Funding: Baekeland
- Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stage (EV-TRACE)From1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responsesFrom1 Oct 2019 → 30 Sep 2022Funding: IOF - technology validation in lab
- Development and validation of sampling and rapid assay methods for vedozilumab and ustekinumab therapeutic drug monitoringFrom1 Dec 2018 → 30 Nov 2020Funding: Foreign private sponsor - undefined
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
Publications
41 - 50 of 197
- Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?(2020)
Authors: Paul Declerck
Pages: 35 - 64 - Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools(2020)
Authors: Paul Declerck
- Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.(2019)
Authors: Machteld Sillen, Sergei Strelkov, Paul Declerck
Pages: 681 - 692 - Bridging the Clinical Gap for DNA-Based Antibody Therapy Through Translational Studies in Sheep(2019)
Authors: Kevin Hollevoet, Stéphanie De Vleeschauwer, Giles Vermeire, Nick Geukens, Paul Declerck
Pages: 1431 - 1443 - The rise of oncology biosimilars: from process to promise(2019)
Authors: Paul Declerck
Pages: 3255 - 3265 - The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars(2019)
Authors: Liese Barbier, Paul Declerck, Steven Simoens, Patrick Neven, Arnold Vulto, Isabelle Huys
Pages: 199 - 210 - Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics(2019)
Authors: Paul Declerck
- Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting(2019)
Authors: Evelien Moorkens, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
Pages: 285 - 297 - Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting(2019)
Authors: Evelien Moorkens, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
Pages: 299 - 306 - Demystifying biosimilars: development, regulation and clinical use(2019)
Authors: Paul Declerck
Pages: 777 - 790
Patents
1 - 1 of 1
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1